Moderna (NASDAQ:MRNA) Announces Quarterly Earnings Results

Moderna (NASDAQ:MRNA - Get Free Report) posted its earnings results on Thursday. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($1.89) by $1.92, Briefing.com reports. The business had revenue of $1.90 billion for the quarter, compared to analysts' expectations of $1.25 billion. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business's revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.39) earnings per share.

Moderna Trading Down 6.5 %

• 3 Beaten-Down Stocks Ready for a Comeback

MRNA traded down $3.29 during trading on Friday, hitting $46.99. The company's stock had a trading volume of 10,256,108 shares, compared to its average volume of 4,473,774. Moderna has a twelve month low of $46.57 and a twelve month high of $170.47. The firm's 50 day moving average price is $62.46 and its 200-day moving average price is $99.62. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The stock has a market cap of $18.06 billion, a PE ratio of -3.08 and a beta of 1.69.

Insider Activity

In other Moderna news, CFO James M. Mock sold 715 shares of the firm's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares of the company's stock, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James M. Mock sold 715 shares of the company's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company's stock, valued at $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,184 shares of company stock valued at $238,531 over the last quarter. Company insiders own 15.20% of the company's stock.

Wall Street Analyst Weigh In

• Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity

Several equities research analysts have recently weighed in on the company. TD Cowen decreased their price objective on Moderna from $70.00 to $60.00 and set a "hold" rating for the company in a report on Friday, September 13th. Barclays reduced their target price on shares of Moderna from $125.00 to $111.00 and set an "overweight" rating for the company in a report on Friday. Sanford C. Bernstein initiated coverage on Moderna in a research report on Thursday, October 17th. They set a "market perform" rating and a $55.00 price objective for the company. JPMorgan Chase & Co. dropped their target price on Moderna from $70.00 to $59.00 and set an "underweight" rating on the stock in a report on Monday. Finally, Oppenheimer cut shares of Moderna from an "outperform" rating to a "market perform" rating in a research note on Friday, September 13th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Moderna currently has a consensus rating of "Hold" and an average target price of $93.18.

Check Out Our Latest Report on MRNA

About Moderna

• GeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Read More

• Five stocks we like better than Moderna
• Stock Trading Terms - Stock Terms Every Investor Needs to Know
• Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
• What is the Nasdaq? Complete Overview with History
• The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
• Insider Trades May Not Tell You What You Think
• The Top 5 Performing S&P 500 Stocks YTD in 2024

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ 625,000% Gain (From Crypto Swap Profits) (Ad)

Should you invest $1,000 in Moderna right now?

Before you consider Moderna, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.

While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here